

**CANCER PHARMACOGENOMICS: THE RELEVANCE OF GENETIC
PROFILE IN OPTIMIZATION DRUG THERAPY FOR
AZATHIOPURINE AND 5-FLUOROURACIL**

**INSTITUT PENGURUSAN PENYELIDIKAN (RMI)
UNIVERSITI TEKNOLOGI MARA
40450 SHAH ALAM, SELANGOR
MALAYSIA**

DISEDIAKAN OLEH :

PROF MADYA DR TEH LAY KEK (PRINCIPLE INVESTIGATOR)


PROF DR MOHD ZAKI SALLEH (CO-INVESTIGATOR)

DISEMBER 2010

PROJECT TEAM MEMBERS

PROF. MADYA DR. TEH LAY KEK


Project Leader



.....
Signature


Project Members

PROF. DR. MOHD ZAKI SALLEH



.....
Signature

HAZWANIE BT HASHIM



.....
Signature

ABSTRACT

Title:

Introduction: Pharmacogenomic studies contribute to genetic information in preventing severe side effects of drugs. Genetic polymorphisms in drug metabolizing enzymes such as dihydropyrimidine dehydrogenase (DPD) had been associated with variable clinical outcomes in many commonly prescribed chemotherapy drugs including 5-Fluorouracil and irinotecan.

Objectives: The review of literature had shed lights to the importance and possible impact of genetic polymorphism of *DPYD* and *TPMT* in individualization of drug therapy for 5-FU and thiopurines. However, there were no data reported for Malaysian. Current study thus aimed to explore the role of pharmacogenetics in personalized medicine in our own population.

Materials and methods: Genotyping methods for *DPYD* and *TPMT* were developed using dHPLC and allele specific PCR respectively. 5-FU levels were measured in colorectal cancer patients using developed method. DNA from healthy volunteers and patients were screened.

Results: Genotyping of *DPYD* had detected one reported mutation *DPYD*5*, two new mutations in exon 14 1823 T>C and 1827 G>A and one intronic region of exon 13, 13 IVS-11G>A with allele frequencies of 14.5%, .9.1%, 9.1% and 0.9% respectively. Genotyping for *TPMT* revealed 7 (7%) to be heterozygous for *TPMT* variant alleles. The predominant allele detected is *TPMT*3C* and is in concordance with previous studies done on Southeast Asian populations.

TABLE OF CONTENTS

ABSTRACT	i
ACKNOWLEDGEMENTS	ii
TABLE OF CONTENTS	iii
LIST OF TABLES	viii
LIST OF FIGURES	xi
LIST OF PLATES	x
CHAPTER 1: LITERATURE REVIEW AND INTRODUCTION	
1.1: COLORECTAL CANCER	1
1.2: CHEMOTHERAPEUTIC DRUGS FOR ADVANCED COLORECTAL CANCER	1
1.2.1 5-FLUOROURACIL (5-FU)	2
1.2.1.1 PHARMACOLOGY OF 5-FU	2
1.2.2 THIOPURINES	3
1.2.2.1 PHARMACOLOGY OF THIOPURINES	3
1.3: PROBLEMS IN CHEMOTHERAPY TREATMENT	5
1.4: DIAGNOSTIC ROLE OF PHARMACOGENETICS IN PREVENTING ADVERSE DRUG REACTION OF CHEMOTHERAPUTIC AGENT	5

1.4.1: DRUG METABOLISING ENZYME (DME)	6
1.4.2: CANDIDATE GENE STRATEGIES FOR CANCER PHARMACOGENOMICS	6
1.4.2.1: <i>DPYD</i>	6
1.4.2.2: <i>TPMT</i>	7
 CHAPTER 2: DEVELOPMENT AND VALIDATION OF DENATURING HIGH LIQUID CHROMATOGRAPHY (DHPLC) FOR SCREENING <i>DPYD</i> VARIANTS	
2.1: INTRODUCTION	11
2.2: STUDY METHODOLOGY	12
2.3: OBJECTIVES	13
2.4: SUBJECTS RECRUITMENT	13
2.5: INCLUSION CRITERIA	14
2.6: EXCLUSION CRITERIA	14
2.7: MATERIALS	15
2.8: METHODOLOGY	17
2.8.1 PRIMER SELECTION	17
2.8.2: RECONSTITUTION OF PRIMERS	18
2.8.3: PREPARATION OF PCR PRODUCTS FOR dHPLC ANALYSIS	22
2.8.4: VALIDATION OF DHPLC ASAY	23